|
 |
 |
Plasil dosage oral formulation contains 0.5 mg of fluconazole 0.025%, a 2.4% sodium salt; 4,5-diamidino-2-phenylindole, anhydrous; 7-cyano-4-(2-fluorophenyl)-2-(m-chlorophenyl)indole, dicamphor, methyl-cassolin; fluadiamide salt, sodium salt and 2.5% potassium in a total dry matter of 0.2% by weight. Dicamphor (diamide-3-amidino), is also called tetracycline; 2 - 4, [1 R] fluconazole; fluconazole (Sigma-Aldrich) is a quinolone antibiotic of the broad spectrum used in treatment of bacterial infection; fluconazole (Sigma-Aldrich) is an acyclovir antifungal, antiviral and antibiotics.
[0080] "Fluconazole" for the treatment of a fungal keratotic lesion in non-dislodged epithelial unit adults has a mean concentration of 12.5 mcg/ml [see USP].
[0081] "Fluconazole" or "fluconazole and fluconazole salts" for the treatment of keratopoospermia in an adults, has a mean concentration of 2.6 mcg/ml [see USP].
[0082] "Glucocorticoids" for the treatment of acute and chronic renal failure inflammation due to diseases of the kidney, skin and pituitary gland, have a mean concentration of 6.4 mcg/ml [see USP].
In certain embodiments, the invention provides a method of treating fungal disease by administering to a subject an effective amount of agent the invention. Such effective amount can be, for example, an effective amount with respect to a peak serum level of the specific compounds which reduce disease activity of the fungus, which, for example can exceed the maximum daily administration limit for an individual.
[0083] In various plasil qual generico embodiments, the invention provides a prophylactic method of treating disorder the skin resulting from diseases of the upper respiratory tract as indicated, for example, by an upper respiratory tract allergy; or a skin disorder for which topical treatment is effective in clinical use, such as atopic dermatitis, eczema, psoriasis, |
|